within Pharmacolibrary.Drugs.C_CardiovascularSystem.C03A_LowCeilingDiureticsThiazides.C03AA07_Cyclopenthiazide;
model Cyclopenthiazide 
   extends Pharmacolibrary.Drugs.ATC.C.C03AA07;

  annotation(Documentation(
    info ="<html><body><p>Cyclopenthiazide is a thiazide diuretic once used to treat hypertension and edema associated with congestive heart failure and certain renal or hepatic conditions. It is no longer widely marketed or approved in many countries as of 2024, due to the availability of newer and safer diuretics.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult patients after typical oral dose, based on similarity with other thiazide diuretics; no direct human PK studies published for cyclopenthiazide.</p><h4>References</h4><ol><li><p>Krum, H, et al., &amp; Louis, WJ (1992). Steady-state pharmacokinetics and pharmacodynamics of cilazapril in the presence and absence of cyclopenthiazide. <i>Journal of cardiovascular pharmacology</i> 20(3) 451–457. DOI:<a href=&quot;https://doi.org/10.1097/00005344-199209000-00017&quot;>10.1097/00005344-199209000-00017</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1279292/&quot;>https://pubmed.ncbi.nlm.nih.gov/1279292</a></p></li><li><p>Louis, WJ, et al., &amp; Vajda, FJ (1978). Labetalol: bioavailability, drug plasma levels, plasma renin and catecholamines in acute and chronic treatment of resistant hypertension. <i>Australian and New Zealand journal of medicine</i> 8(6) 602–609. DOI:<a href=&quot;https://doi.org/10.1111/j.1445-5994.1978.tb04847.x&quot;>10.1111/j.1445-5994.1978.tb04847.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/285681/&quot;>https://pubmed.ncbi.nlm.nih.gov/285681</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Cyclopenthiazide;
